Verona Pharma的VRNA-101显示,在2025年问题2中,治疗肺高血压、增加库存和投资者信心的前景良好。 Verona Pharma's VRNA-101 showed promise in treating lung hypertension, boosting stock and investor confidence in Q2 2025.

Verona Pharma报告说,其吸入药物的第二阶段临床试验VRNA-101(治疗肺动脉高血压)取得了积极成果,导致2025年第二季度库存激增。 Verona Pharma reported positive results from a Phase 2 clinical trial of its inhaled drug, VRNA-101, for treating pulmonary arterial hypertension, driving a significant stock surge in the second quarter of 2025. 试验显示,在锻炼能力和肺功能方面有所改善,提高了投资者的信心。 The trial showed improvements in exercise capacity and lung function, boosting investor confidence. 该公司还宣布了在监管战略方面取得的进展以及与卫生当局正在进行的讨论,以支持今后的批准工作。 The company also announced progress in its regulatory strategy and ongoing discussions with health authorities to support future approvals.